Kinetic Stabilizers for Amyloidogenic Light Chains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for light chain amyloidosis, such as chemotherapy, achieve complete eradication of clonal plasma cells in only 30-40% of patients and often result in limited organ response, with patients with cardiac involvement being too sick to tolerate chemotherapy, leading to high mortality and morbidity.
Innovation Solution
Development of small molecule kinetic stabilizers that bind to conserved residues at the variable domain-variable domain interface of immunoglobulin light chains, stabilizing the native dimer structure and preventing conformational excursions that lead to aggregation and organ toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to eradicate clonal plasma cells, then the cancer component is targeted, but complete eradication is achieved in only 30-40% of patients and most eventually relapse
Solution Approach 1:
The kinetic stabilizer is administered before chemotherapy to stabilize the light chain conformation and prevent aggregation. This preliminary stabilization ensures that even if chemotherapy fails to completely eradicate plasma cells, the light chains remain in a non-toxic conformation, preventing relapse and improving organ response.
Solution Approach 2:
The kinetic stabilizer acts as an intermediary between the light chain and the aggregation process. It binds to the light chain at the variable domain-variable domain interface, stabilizing the native dimer structure and preventing conformational excursions that would lead to aggregation and toxicity, thereby complementing the chemotherapy's action.
2Reliability
If chemotherapy is used to treat light chain amyloidosis, then clonal plasma cells are targeted, but patients with cardiac involvement are too sick to tolerate chemotherapy, leading to high mortality and morbidity
Solution Approach 1:
The kinetic stabilizer provides preliminary protection by stabilizing light chains and preventing aggregation before chemotherapy is administered. This allows cardiac patients to receive chemotherapy with reduced risk, as the stabilizer mitigates the proteotoxicity that would otherwise be exacerbated by chemotherapy-induced light chain release.
Solution Approach 2:
The kinetic stabilizer converts the potentially harmful effect of chemotherapy (release of unstable light chains that could aggregate) into a beneficial outcome by ensuring that light chains remain stabilized throughout the chemotherapy process, thereby protecting cardiac patients from worsening toxicity.
3Stability of the object's composition
If small molecule kinetic stabilizers bind to conserved residues at the variable domain-variable domain interface, then the native dimer structure is stabilized and conformational excursions are prevented, but this requires specific binding site recognition
Solution Approach 1:
The kinetic stabilizer is designed to bind to conserved residues at the variable domain-variable domain interface, which are present across different light chain sequences. This universal binding approach allows a single molecule design to stabilize multiple different light chains, reducing the need for patient-specific customization while maintaining effectiveness.
Solution Approach 2:
The small molecule kinetic stabilizer changes the conformational parameters of the light chain by binding to the variable domain interface. This binding restricts the conformational space available to the light chain, preventing excursions to aggregation-prone conformations and stabilizing the native dimer structure through altered energetic parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule kinetic stabilizers effectively stop light chain conformational changes at the beginning of the aggregation cascade, potentially halting disease progression in light chain amyloidosis without the need to understand non-native structure-proteotoxicity relationships, offering a new treatment option for patients who cannot tolerate traditional chemotherapy.
Implementation Method 1
The small molecule kinetic stabilizers disclosed herein bind to conserved residues at the variable domain-variable domain interface in the native light chain dimer, stabilizing this putative non-toxic structure against the conformational changes and aggregation that cause light chain amyloidosis.
Data Source
AI summary
In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.